Jan 26 (Reuters) - The U.S. Food and Drug Administration said on Thursday that AstraZeneca's COVID-19 antibody cocktail Evusheld is not currently authorized for use in the United States until further notice by the agency. (Reporting by Bhanvi Satija in Bengaluru)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,076 GBX | -0.23% | +1.14% | +13.96% |
07-15 | Global markets live: Airbus, Burberry, AT&T, Boeing, Vinfast... | |
07-15 | AstraZeneca: acquisition of Amolyt Pharma finalized | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.96% | 244B | |
+62.92% | 856B | |
+39.26% | 631B | |
-3.64% | 359B | |
+18.30% | 325B | |
+9.19% | 297B | |
+5.89% | 234B | |
+16.77% | 226B | |
+16.30% | 177B | |
+2.29% | 165B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- U.S. FDA withdraws authorization for AstraZeneca's Evusheld